Lymphoma-targeted Treatment Using a Folic Acid-decorated Vincristine-loaded Drug Delivery System

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2018 May 2

PMID 29713144

Citations 10

Authors

Lei Qiu

Chao Dong

Xuan Kan

Affiliations

Soon will be listed here.

Abstract

Purpose: B-cell lymphoma is the most frequently diagnosed lymphoid tumor. Folic acid (FA)-decorated systems were found to be preferentially internalized on the B-cell lymphoma cell line which is reported to express the folate receptor. This study was designed to develop an FA-decorated vincristine (VCR)-loaded system for targeted lymphoma treatment.

Methods: FA-decorated lipid was synthesized. VCR-loaded lipid-polymer hybrid nanoparticles (LPNs) were fabricated. In vitro cell lines and an in vivo lymphoma animal model was used to evaluate the anti B-cell lymphoma effect.

Results: FA-decorated, VCR-loaded LPNs (FA-VCR/LPNs) have shown a targeted effect in delivery to B-cell lymphoma cells. FA-VCR/LPNs also showed the highest anti-tumor effect in murine-bearing lymphoma xenografts.

Conclusion: FA-VCR/LPNs can achieve targeted delivery of VCR, bring about an outstanding therapeutic effect to treat lymphoma, and also reduce the systemic toxicity. FA-VCR/LPNs could be an excellent system for lymphoma therapy.

Citing Articles

Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations.

Zhang Z, Li M, Zhang X, Zhou F Int J Nanomedicine. 2024; 19:9659-9688.

PMID: 39309188 PMC: 11416109. DOI: 10.2147/IJN.S479212.

Panobinostat-loaded folate targeted liposomes as a promising drug delivery system for treatment of canine B-cell lymphoma.

Andre A, Dias J, Aguiar S, Leonardo A, Nogueira S, Amaral J Front Vet Sci. 2023; 10:1236136.

PMID: 37711439 PMC: 10498770. DOI: 10.3389/fvets.2023.1236136.

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models.

Capolla S, Argenziano M, Bozzer S, DAgaro T, Bittolo T, De Leo L Front Immunol. 2023; 14:1200310.

PMID: 37359561 PMC: 10285521. DOI: 10.3389/fimmu.2023.1200310.

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.

Li J, Wang Q, Han Y, Jiang L, Lu S, Wang B J Hematol Oncol. 2023; 16(1):65.

PMID: 37353849 PMC: 10290401. DOI: 10.1186/s13045-023-01460-2.

Synthesis and Characterization of Folic Acid-Functionalized DPLA-co-PEG Nanomicelles for the Targeted Delivery of Letrozole.

Rostami N, Gomari M, Abdouss M, Moeinzadeh A, Choupani E, Davarnejad R ACS Appl Bio Mater. 2023; 6(5):1806-1815.

PMID: 37093754 PMC: 10629236. DOI: 10.1021/acsabm.3c00041.

References

Chen W, Completo G, Sigal D, Crocker P, Saven A, Paulson J . In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood. 2010; 115(23):4778-86. PMC: 2890185. DOI: 10.1182/blood-2009-12-257386. View

Kim C, Lim S, Kim J . In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. J Control Release. 2011; 157(2):190-5. DOI: 10.1016/j.jconrel.2011.09.066. View

Knapp C, Whitehead K . In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma. Expert Opin Drug Deliv. 2014; 11(12):1923-37. DOI: 10.1517/17425247.2014.945419. View

Salvador-Morales C, Zhang L, Langer R, Farokhzad O . Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009; 30(12):2231-40. PMC: 2699891. DOI: 10.1016/j.biomaterials.2009.01.005. View

Tuscano J, Martin S, Ma Y, Zamboni W, ODonnell R . Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010; 16(10):2760-8. DOI: 10.1158/1078-0432.CCR-09-3199. View

Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C . Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine. 2015; 10:2101-14. PMC: 4368035. DOI: 10.2147/IJN.S77667. View

Ni S, Qiu L, Zhang G, Zhou H, Han Y . Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers. Int J Nanomedicine. 2017; 12:1565-1576. PMC: 5338998. DOI: 10.2147/IJN.S120685. View

Siwowska K, Schmid R, Cohrs S, Schibli R, Muller C . Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization. Pharmaceuticals (Basel). 2017; 10(3). PMC: 5620616. DOI: 10.3390/ph10030072. View

Berguig G, Convertine A, Shi J, Corinna Palanca-Wessels M, Duvall C, Pun S . Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate. Mol Pharm. 2012; 9(12):3506-14. PMC: 3600396. DOI: 10.1021/mp300338s. View

10.

Oliveira Silva C, Rijo P, Molpeceres J, Figueiredo I, Ascensao L, Fernandes A . Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-inflammatory treatment. Int J Pharm. 2015; 493(1-2):271-84. DOI: 10.1016/j.ijpharm.2015.07.044. View

11.

Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R . Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54(4):987-92. View

12.

Xiao K, Luo J, Li Y, Lee J, Fung G, Lam K . PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release. 2011; 155(2):272-81. PMC: 3196055. DOI: 10.1016/j.jconrel.2011.07.018. View

13.

Li Y, Wu H, Yang X, Jia M, Li Y, Huang Y . Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. Mol Pharm. 2014; 11(8):2915-27. DOI: 10.1021/mp500254j. View

14.

Hadinoto K, Sundaresan A, Cheow W . Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013; 85(3 Pt A):427-43. DOI: 10.1016/j.ejpb.2013.07.002. View

15.

Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X . In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 2009; 379(1):181-6. DOI: 10.1016/j.ijpharm.2009.06.022. View

16.

Shankland K, Armitage J, Hancock B . Non-Hodgkin lymphoma. Lancet. 2012; 380(9844):848-57. DOI: 10.1016/S0140-6736(12)60605-9. View

17.

Xu Y, Qiu L . Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes. Int J Nanomedicine. 2015; 10:4225-37. PMC: 4494179. DOI: 10.2147/IJN.S84555. View

18.

Baek J, Kim J, Park J, Cho C . Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Int J Nanomedicine. 2015; 10:5397-405. PMC: 4554395. DOI: 10.2147/IJN.S86474. View

19.

Park J, Fong P, Lu J, Russell K, Booth C, Saltzman W . PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 2009; 5(4):410-8. PMC: 2789916. DOI: 10.1016/j.nano.2009.02.002. View

20.

Pan X, Wang H, Shukla S, Sekido M, Adams D, Tjarks W . Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjug Chem. 2002; 13(3):435-42. DOI: 10.1021/bc015557y. View